LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Начало・Списък с акции・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

22.35 -0.62

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.24

Максимум

22.89

Ключови измерители
By Trading Economics
Приходи	202M 274M
Продажби	5.4M 284M
P/E Средно за сектора	9.565 49.8
Марж на печалбата	96.33
Служители	796
EBITDA	-21M 26M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+44.81% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-385M 3.8B
Предишно отваряне	22.97
Предишно затваряне	22.35

Настроения в новините

By Acuity

17%

83%

37 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

14.845 / N/A Подкрепа & съпротива

ACADIA Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Canada's Job Market Sees Worst Start in Years -- Market Talk

8.05.2026 г., 15:36 ч. UTC

Пазарно говорене

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8.05.2026 г., 15:20 ч. UTC

Пазарно говорене

'Altcoin Season' Indicator on the Rise -- Market Talk

8.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Печалби

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8.05.2026 г., 15:05 ч. UTC

Пазарно говорене

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8.05.2026 г., 14:42 ч. UTC

Пазарно говорене

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8.05.2026 г., 14:39 ч. UTC

Пазарно говорене

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

44.81% нагоре

12-месечна прогноза

Среден 32.67 USD 44.81%

Висок 38 USD

Нисък 24 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на ACADIA Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

14.845 / N/AПодкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

37 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.